International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

placeholder

Immunosuppressive Drugs Committee

Last Updated: Saturday, 28 August 2021 13:25

Stein Bergan

Chair

Stein Bergan
University of Oslo, Norway

 contactus273x169

Contact Us
Scientific Committees
Immunosuppressive Drugs Committee
Satohiro Masuda

Vice-Chair

Satohiro Masuda
Himeji Dokkyo University, Japan

Purpose of the Committee

  • To provide evidence-based recommendations for TDM of immunosuppressive agents.
  • To promote the knowledge and understanding of immunosuppressive drug analysis and interpretation of results.
  • To enhance communication between scientists and physicians of all disciplines involved in TDM of immunosuppressive drugs.
  • To encourage the effective application of TDM in transplant medicine, with the aim of optimizing clinical drug use and maximizing the clinical and economic benefits.

Committee Initiatives Currently in Progress (2021)

  • Standardization of ISD TDM Working Group (Leaders: C. Seger, L. Langman) A joint committee with IFCC.
  • An initiative to establish a course in TDM related to transplantation, still a plan at an early stage. Suggested as a course to follow online. Questions need to be solved upfront, regarding target audience and level, scope of the course and included topics, format and platform for presentations of the course. First step is to establish a group of members to address this.

Scientific Contributions

  • 2021 Publication in TDM: Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, (The Immunosuppressive Drugs Scientific Committee: Bergan, Brunet, Hesselink & al.), Ther Drug Monit, PMID: 33711005  DOI: 10.1097/FTD.0000000000000871
  • 2021 Publication in Compass: Don’t get lost in busulfan translation, S.Bergan, Compass vol 20 issue 2, June 2021
  • Publication in TDM: Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions. Elens & al.
  • Publication in TDM: Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) Expert Panel. Lemaitre & al.
  • Publication in Compass: Report on the symposium therapeutic drug monitoring of immunosuppressants: clinical challenges and analytical issues at the 16th congress of the Asian society of transplantation. S. Pattanaik.
  • Publication in Compass: The potential of the IATDMCT Scientific Committees. S. Bergan.

Additional Committee Resources

  • Biomarker Working Group (Leader U.Christans).
  • Standardization of ISD TDM Working Group. (Leaders: C. Seeger, L. Langman). Joint committee with IFCC.
  • Intracellular tacrolimus measurement Working Group. (Leader: F. Lemaitre).

Minutes of Committee Meetings